DecisionLine adds high-end exploratory/translational medicine capabilities and world-leading scientific psychopharmacology expertise; supports Kendle
strategic initiative to drive growth in its early phase business
CINCINNATI, June 2 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading global full-service clinical research organization (CRO), today announced the acquisition of DecisionLine Clinical Research Corporation (DecisionLine Clinical Services), a privately owned, early phase CRO with a state-of-the-art medical facility in Toronto, Canada. DecisionLine specializes in the conduct of Phase I studies involving the measurement of pharmacodynamic effects of central nervous system (CNS) drugs, and is recognized worldwide as a leader in the conduct of human abuse liability studies and the assessment of abuse potential and risk mitigation. The company brings to Kendle extensive world-class scientific expertise with psychopharmacology high-end exploratory/translational medicine capabilities, from first-in-human to proof-of-concept trial conduct, as well as drug development consulting, medical writing, data management, biostatistics and other support services. Kendle acquired DecisionLine for an undisclosed cash amount. Specific terms of the transaction were not disclosed. The acquired business will report into Philip J.W. Davies, Vice President, Early Phase.
"With Phase I growth expected to outpace the broader outsourcing market
at approximately 15 percent annually, early phase development remains an
important need for our customers and an area of significant growth
|SOURCE Kendle International Inc.|
Copyright©2008 PR Newswire.
All rights reserved